title: Prostate specific antigen through the years.
abstract: PSA was first identified in the 1960s. Some controversy exist as to who should be credited with its discovery as different groups, simultaneously, isolated the same protein but gave it a different name. PSA was firstly approved by FDA in 1986 as a test to aid the management of patients diagnosed with prostate cancer. In 1994, it was approved by the FDA as a diagnostic tool and up to date its beneficial role as a screening test is largely unknown. The results of the PLCO and ERSPC trials are awaited. Increasing interest is also emerging on the use of PSA as a tool in the management of BPH. Recently some embryonic data on the use of other novel markers such as EPCA and prostasomes is emerging and the data on PCA3 as a diagnostic tool for prostate cancer is maturing.
authors.affiliation: Department of Urology, Kings College Hospital, Denmark Hill, London, United Kingdom. ckouriefs@hotmail.com
authors.forename: Chryssanthos
authors.initials: C
authors.lastname: Kouriefs
authors.forename: Mukhtar
authors.initials: M
authors.lastname: Sahoyl
authors.forename: Philippe
authors.initials: P
authors.lastname: Grange
authors.forename: Gordon
authors.initials: G
authors.lastname: Muir
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood* / Q000266:history; D049673:History, 20th Century; D006801:Humans; D007564:Japan; D008297:Male; D008403:Mass Screening; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000266:history; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000266:history / Q000276:immunology; D012680:Sensitivity and Specificity; D014481:United States
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen